JESSICA SPARKS: Open Payments
NPI 1760059497 · FRENCHBURG, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$947 in 52 payments from 13 companies in 2025. Trend: 2023 $692 · 2024 $382 · 2025 $947
Food & beverage: $947
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $220 |
| ABBVIE INC. | 9 | $159 |
| GENZYME CORPORATION | 4 | $122 |
| GlaxoSmithKline, LLC. | 5 | $104 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Indivior Inc. | 4 | $67 |
| Lilly USA, LLC | 3 | $49 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 1 | $34 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $27 |
Products named: CAPLYTA, VRAYLAR, DUPIXENT, TRELEGY ELLIPTA, REXULTI, SUBLOCADE, MOUNJARO, FANAPT.
Industry payments across KY — which companies pay providers there.
